Publication date: Sep 17, 2025
The pandemic character of coronavirus disease-19 (COVID-19) requires strategy changes designed to guarantee the safety of patients and health-care professionals. We are greatly concerned by the limitations in the operation of pulmonary function test (PFT) laboratories, since there is a high risk of disease progression in patients with chronic pulmonary diseases, and we are now faced by the influx of a new group of individuals in the recovery phase of post-COVID-19-syndrome that requires evaluation and follow-up of their respiratory function. To reestablish the operation of PFT laboratories limiting the risk of cross-contamination, we herein present the consensus reached by a group of experts in respiratory physiology, most of whom work in PFT laboratories in several Latin-American countries, on the applicable recommendations for severe acute respiratory syndrome coronavirus 2 pneumonia survivors when undergoing PFT. We present the safety and hygiene measures that must be adopted in laboratories or centers where PFT is conducted in adults and/or children. These recommendations answer the following questions: which PFT is most recommended in subjects that have recovered from COVID-19; what quality control and safety measures should PFT laboratories implement during this pandemic? And how should we approach non-COVID-19 patients requiring PFT?
| Concepts | Keywords |
|---|---|
| Coronavirus | Coronavirus disease-19 |
| Latin | Pulmonary function tests |
| Pandemic | |
| Pneumonia | |
| Professionals |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | coronavirus disease-19 |
| disease | IDO | role |
| drug | DRUGBANK | Bentiromide |
| disease | MESH | disease progression |
| disease | MESH | pulmonary diseases |
| disease | MESH | syndrome |
| disease | MESH | pneumonia |
| disease | IDO | quality |